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Biotransformation of fluorophenyl pyridine carboxylic acids by the 
model fungus Cunninghamella elegans 
1.  Fluorine plays a key role in the design of new drugs and recent FDA 
approvals included two fluorinated drugs, tedizolid phosphate and vorapaxar, 
both of which contain the fluorophenyl pyridyl moiety. 
2.  To investigate the likely phase I (oxidative) metabolic fate of this group, 
various fluorinated phenyl pyridine carboxylic acids were incubated with the 
fungus Cunninghamella elegans, which is an established model of mammalian 
drug metabolism.   
3.  19F NMR spectroscopy established the degree of biotransformation, which 
varied depending on the position of fluorine substitution, and GC-MS identified 
alcohols and hydroxylated carboxylic acids as metabolites. The hydroxylated 
metabolites were further structurally characterised by NMR, which demonstrated 
that hydroxylation occurred on the 4’ position; fluorine in that position blocked 
the hydroxylation.   
4.  The fluorophenyl pyridine carboxylic acids were not biotransformed by rat 
liver microsomes and this was a consequence of inhibitory action, thus the fungal 
model was crucial in obtaining metabolites to establish the mechanism of 
catabolism. 
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Introduction 
The unusual physicochemical properties of fluorine, such as the small van der Waals 
radius, high electronegativity and the strength of the C-F bond make it a very important 
element in the pharmaceutical industry.  Incorporation of fluorine into 
pharmacologically active compounds results in increased lipophilicity, improved 
metabolic stability and enhanced potency (Murphy and Sandford, 2015).  The 
importance of fluorine is reflected in the numbers of new fluorinated drugs that are 
either on the market or in development.  In 2014 the US Food and Drug Administration 
approved 41 new molecular entities and of the 27 small molecules, eight contain 
fluorine (Jarvis, 2015).  Two examples are shown in Figure 1: Sivextro® (tedizolid 
phosphate) is manufactured by Cubist Pharmaceuticals for the treatment of skin 
infections, and Zontivity® (vorapaxar) from Merck is an anti-clotting agent.  Both 
drugs have a fluorophenyl substituted pyridyl moiety and the oxidative metabolism of 
this group has not been determined.  Therefore, in this study the biotransformation of 
various fluorophenyl pyridine carboxylic acids was investigated in a fungus and 
microsomes to establish the phase I (oxidative) metabolites. 
Cunninghamella spp. are fungi that have been used extensively as microbial 
models of drug metabolism for decades, in particular C. elegans, C. echinulata and C. 
blakesleeana (Asha and Vidyavathi, 2009).  They are easily cultivated and have 
cytochrome P450 activity, which has a very broad substrate range (Murphy, 2015), thus 
can yield phase I (oxidative) metabolites of many drugs, including those that contain 
fluorine (Amadio et al., 2010, Amadio and Murphy, 2011).  They also have enzymes 
associated with phase II (conjugative) metabolism, such as sulfotransferase, glucosyl 
transferase and glutathione S-transferase (Zhang et al., 1996).  Furthermore, C. elegans 
can be employed in the design of fluorinated drugs, by identifying through 
biotransformation metabolically labile sites on non-fluorinated drug leads, which can 
then be modified by synthesis to contain fluorine at that specific position, thereby 
prolonging metabolic half-life (Bright et al., 2013, Shaughnessy et al., 2014).  Amongst 
the many xenobiotics that Cunninghamella spp. can biotransform are nitrogen-
containing heterocycles such as quinolone (Sutherland et al., 1994), cinnoline 
(Sutherland et al., 1998) and phenothiazine (Sutherland et al., 2001), and in the case of 
phenothiazine, the metabolites were analogous to those produced in mammals.  In the 
present study the biotransformation of several fluorophenyl-substituted pyridine 
carboxylic acids (Figure 2) by C. elegans was investigated, as a model of the likely 
phase I mammalian metabolism of drugs that contain similar functionalities, such as 
Sivextro and Zontivity.  The catabolism of the compounds in rat liver microsomes was 
also investigated. 
Materials and methods 
Chemicals 
5-Phenylpyridine-2-carboxylic acid 1 (95%) was acquired from Maybridge (Thermo 
Scientific). 5-(3-Fluorophenyl) pyridine-3-carboxylic acid 2, 5-(2-fluorophenyl) 
pyridine-3-carboxylic acid 3, 5-(4-fluorophenyl) pyridine-3-carboxylic acid 4, 6-(2-
fluorophenyl) pyridine-3-carboxylic acid 5, were purchased from Sigma Aldrich.  
Culture conditions 
Cunninghamella elegans was cultivated on sabouraud dextrose agar for 120 h at 27 °C. 
Inoculum was prepared by homogenising the mycelium in sterile 0.8% NaCl (100 mL). 
The homogenate (5 mL) was used to inoculate 250 mL Erlenmeyer flasks containing 45 
mL sabouraud dextrose broth, then incubated 72 h with rotary agitation (150 rpm) at 28 
°C. The compounds were solubilised in dimethyl sulfoxide, 50 μL was added to the 
flask and incubation was continued for a further 24 h (unless stated otherwise). 
Supernatant from the biotransformation experiments was extracted in ethyl acetate; the 
solvent was removed under reduced pressure and the residue re-dissolved in methanol. 
Isolation of biotransformation products 
Organic extracts from shake flasks were analysed by reversed-phase high-performance 
liquid chromatography (HPLC) with a Varian prostar HPLC system equipped with 
Zorbax SB-C18 5 μm 4.6 × 150 mm column (Agilent technologies) and a UV–Vis 
detector monitoring at 250 nm. Analytes were eluted with a gradient of acetonitrile / 
water (20–80 % acetonitrile) over 35 min at a flow rate of 1 mL/min. The metabolites 
were purified by semi-preparative HPLC with an Ascentis C18 column (15 cm×10 mm, 
5 µm Supelco), with a flow rate of 4mL/min for 35 minutes eluted with a gradient of 
acetonitrile containing trifluoroacetic acid (0.1% v/v)/water (20-80%). Fractions 
containing putative metabolite as indicated by UV absorbance, were pooled and 
extracted in ethyl acetate. To remove residual trifluoroacetic acid, the organic extracts 
were back extracted in an alkaline solution (pH 11). The isolated metabolites were 
confirmed by GC-MS and 19F NMR. 
Analysis of biotransformation products 
Gas chromatography–mass spectrometry analysis was routinely conducted on per 
trimethylsilylated extracts using an Agilent 6890 gas chromatograph coupled to a 5973 
mass selective detector. Silylation was performed by adding 50 μL N-methyl- N-
(trimethyl-silyl) trifluoroacetamide (MSTFA, Sigma) to a dried aliquot of the extracted 
supernatant and heating at 100 °C for 1 h. Derivatised samples (1 µL) were injected in 
the split mode onto a HP-5MS column (30 m × 0.25 mm × 0.25 µm) and the oven 
temperature held at 150 ⁰C for 2 min then raised to 300 ⁰C at 10 ⁰C min-1. The mass 
spectrometer was operated in scan mode. Accurate mass measurements were obtained 
with a LCT time-of-flight mass spectrometer (Waters Corp., USA). 
19F NMR, 1H NMR and 13C NMR spectra were recorded on Varian Inova 400 
MHz or Agilent 126 and 500 MHz spectrometers with DMSO-d6 used as the solvent. 
Chemical shifts (δ) are reported in ppm and coupling constants are given in Hz. 1H 
signals were assigned using 2D homonuclear 1H-1H gradient COSY experiments. The 
1H coupling constants were determined by 1D 1H spectra. 13C signals were assigned 
using 2D heteronuclear 1H-13C and 19F-13C HSQC and 1H-13C HMBC experiments. The 
degree of transformation was determined by 19F NMR spectroscopy of the crude 
reaction mixture. Inversion recovery experiments were performed to measure the 
relaxation time of the different compounds to improve accuracy of 19F NMR analysis 
for quantitative measurement; consequently the relaxation delay was increased to 30 
seconds. 
 
5-(3’-fluoro-4’-hydroxyphenyl) pyridine-3-carboxylic acid 8 
19F NMR (376 MHz, DMSO-d6) δF -135.6 (dd, J = 12.5, 9 Hz), 1H NMR (400 MHz, 
DMSO-d6) δH 10.18 (s, OH-4’), 9.03 (d, J = 2.5 Hz, H-2), 8.96 (d, J = 2 Hz, H-6), 8.36 
(t, J = 2 Hz, H-4), 7.63 (dd, J = 12.5, 2.5 Hz, H-2’), 7.42 (ddd, J = 8.5, 2.5, 1 Hz, H-6’), 
7.04 (dd, J = 9, 8.5 Hz, H-5’), 13C NMR (126 MHz, DMSO-d6) δC 151.9 (C-3’), 151.3 
(C-2), 148.8 (C-6), 134.3 (C-4), 123.8 (C-6’), 118.9 (C-5’), 115.2 (C-2’), HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C12H8FNO3 234.0566; Found 234.0563. 
 
5-(2’-fluoro-4’-hydroxyphenyl) pyridine-3-carboxylic acid 9 
19F NMR (376 MHz, DMSO-d6) δF -116.97 (dd, J = 13, 9.5 Hz), 1H NMR (400 MHz, 
DMSO-d6) δH 10.22 (s, OH-4’), 8.98 (d, J = 2 Hz, H-2), 8.87 (t, J = 2 Hz, H-6), 8.28 (q, 
J = 2 Hz, H-4), 7.46 (dd, J = 9.5, 8.5 Hz, H-6’), 6.75 (dd, J = 8.5, 2.5 Hz, H-5’), 6.65 
(dd, J = 13, 2.5 Hz, H-3’), 13C NMR (126 MHz, DMSO-d6) δC  160.4 (C-2’), 152.7 (C-
6), 148.8 (C-2), 136.5 (C-4), 131.7 (C-6’), 113.0 (C-5’), 103.6 (C-3’),  HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C12H8FNO3 234.0566; Found 234.0571. 
 
6-(2’-fluoro-4’-hydroxyphenyl) pyridine-3-carboxylic acid 10 
19F NMR (376 MHz, DMSO-d6) δF -114.0 (dd, J = 13.5, 9.5 Hz), 1H NMR (500 MHz, 
DMSO-d6) δH 10.40 (s, OH-4’), 9.10 (d, J = 2 Hz, H-2), 8.28 (dd, J = 8.5, 2.5 Hz, H-4), 
7.91 (dd, J = 9.5, 8.5 Hz, H-6’), 7.82 (dd, J = 8.5, 2 Hz, H-5), 6.76 (dd, J = 8.5, 2.5 Hz, 
H-5’), 6.68 (dd, J = 13.5, 2.5 Hz, H-3’), 13C NMR (126 MHz, DMSO-d6) δC 161.4 (C-
2’), 150.7 (C-2), 138.2 (C-4), 132.3 (C-6’), 123.2 (C-5), 112.9 (C-5’), 103.7 (C-3’). 
 
6-(2’-fluorophenyl) pyridine-3-methanol 11 
19F NMR (376 MHz, DMSO-d6) δF -117.44 – -117.53 (m), 1H NMR (500 MHz, DMSO-
d6) δH 8.64 (d, J = 2 Hz, H-2), 7.91 (td, J = 8, 2 Hz, H-5’), 7.81 (dd, J = 8, 2.5 Hz, H-4), 
7.74 (dd, J = 8, 2 Hz, H-5), 7.46 (tdd, J = 7.5, 5, 2 Hz, H-3’), 7.32 (d, J = 8 Hz, H-6’), 
7.30 (dd, J = 8, 5 , H-4’), 5.35 (t, J = 5.5 Hz, H-8), 4.57 (d, J = 5.5 Hz, 2H-7), 13C NMR 
(126 MHz, DMSO-d6) δC   160.3 (C-2’), 148.7 (C-2), 135.5 (C-4), 131.1 (C-3’), 129.9 
(C-5’), 125.3 (C-6’), 124.0 (C-5), 116.6 (C-4’), 60.1 (CH2) , HRMS (ESI-TOF) m/z: [M 
+ H]+ Calcd for C12H10FNO 204.0825; Found 204.0829. 
 
Mammalian biotransformation 
Methods employed in the transformation by rat liver microsomes were similar to that 
described by Obach et al (1998). Rat liver microsomes (1 mg/mL) were incubated for 2 
hours at 37 oC with the compounds 2-5 (0.5 mM, 0.25 mM, 0.125 mM) dissolved in 
DMSO (0.25% v/v), plus magnesium chloride (3.3 mM) and NADPH (1 mM) in a final 
volume of 0.5ml sodium phosphate buffer (25 mM, pH 7). The metabolites were 
extracted using ethyl acetate. Extracts were derivatised and analysed by GC-MS as 
described above except using splitless mode with the oven temperature held at 120 ⁰C 
for 2 min then raised to 300 ⁰C at 10 ⁰C min-1.  Control biotransformation experiments 
were conducted using flurbiprofen as the substrate. To measure the inhibition of the 
fluorophenyl pyridine carboxylic acids on rat liver microsomes, a co-incubation study 
using flurbiprofen (0.5 mM) and titrated concentrations of 2 were added as described 
above. 4’-Hydroxy-flurbiprofen was detected and the transformation efficiency was 
determined through integration of the peaks and expressed as a percentage of the 
combined areas of flurbiprofen and hydroxyflurbiprofen. 
Results 
Biotransformation of fluorophenyl pyridine carboxylic acids 
Initial biotransformation products formed after 2-5 were incubated with the fungus were 
detected by 19F NMR spectroscopy (Table 1).  No abiotic transformation of any of the 
compounds was observed.  Comparison of the resonance integrals indicated that 
compounds 2 and 5 were extensively biotransformed to fluorometabolites after 24 h; 
compound 3 was poorly metabolised and compound 4 was not biotransformed.  GC-MS 
analysis of the fungal extracts after silylation shed further light on the nature of the 
metabolites (Table 2).  No biotransformation product was detected from 4, which is 
consistent with the 19F NMR analysis.  A single metabolite with the expected mass of a 
hydroxylated carboxylic acid (8 and 9, Figure 3) was detected from cultures incubated 
with 2 and 3, respectively. Along with a hydroxylated carboxylic acid (6 and 10), an 
additional metabolite (7 and 11 respectively, Figure 3) was detected from extracts of 
fungal cultures incubated with 1 (non-fluorinated) and 5, respectively.  The mass of the 
derivatives was consistent with that of the (fluoro-) phenyl pyridine alcohol (7 and 11), 
and 1H NMR analysis of the purified fluorometabolite 11 revealed a new doublet for 
methylene (H 4.57 ppm, J = 5.5 Hz) and a new triplet for the –OH (H 5.35 ppm, J = 
5.5 Hz).  Extended incubation with C. elegans for a further 24 h resulted in the 
disappearance of these metabolites and the detection of the mono-hydroxy phenyl 
pyridine carboxylic acids (Figure 4).  Similar reduction and oxidation of carboxyl 
groups has been observed in our previous study on biphenyl carboxylic acids (Bright et 
al., 2013).  
Site of mono-hydroxylation 
Our previous studies on biphenyl systems (Amadio et al., 2010, Bright et al., 2013, 
Shaughnessy et al., 2014) demonstrated that the hydroxylation typically occurs on the 4’ 
(para) position.  Furthermore, when this site is blocked by fluorine, no hydroxylation 
occurs, and the observation that 4 was not biotransformed by the fungus is consistent 
with this.  The hydroxylated fluorometabolites 8, 9 and 10 (Figure 4) were further 
purified from the culture extracts by semi-preparative HPLC and subjected to structural 
characterisation by NMR.  This revealed that the starting substrates 2, 3 and 5 were all 
hydroxylated in the expected 4’ position, since the hydrogens H 7.54 (2), 7.52 ppm (3) 
and 7.37 ppm (5), disappear in the hydroxylated products. This was supported by the 
effect of the hydroxyl group on the splitting of the fluorine signal, changing its 
multiplicity to a doublet of doublets in each case and furthermore, by the strong 
coupling (12.5-13.5 Hz) between the fluorine atoms and their respective ortho 
hydrogens. For example, the coupling of the fluorine (12.5, 9 Hz) in metabolite 8, 
revealed that the hydrogen H 7.63 ppm assigned to the 2’ position, shared a strong  3JHF 
coupling (12.5 Hz). Whereas, its meta hydrogen, H 7.06 assigned to the 5’ position 
shared a 4JHF coupling of 9 Hz. 
Mammalian biotransformation of fluorophenyl pyridine carboxylic acids 
In order to compare the metabolites formed in the fungus with mammalian metabolites, 
compounds 2-5 were incubated with rat liver microsomes.  However, no 
biotransformation products were detected by GC-MS.  To determine if the fluorophenyl 
pyridine carboxylic acids are inhibitors of the microsomal preparations, various 
concentrations of 2 were incubated with microsomes plus another transformable 
substrate, flurbiprofen.  GC-MS analysis of the ethyl acetate extracts demonstrated that 
in the absence of 2 or at a concentration of 0.125 mM of 2, the expected metabolite 4’-
hydroxyflurbiprofen was detected, but in the presence of 0.25 mM of 2, no metabolite 
was detected (Figure 5).  Interestingly, when 0.125 mM of 2 was incubated with the 
microsomes, no biotransformation was observed, even though at this concentration the 
starting compound is not inhibitory to the hydroxylation of flurbiprofen. 
Discussion 
With the exception of the 4’-fluorinated derivative 4, C. elegans biotransformed various 
pyridine carboxylic acids 1- 3 and 5 to phase I (oxidative) metabolites 8-10 that were 
hydroxylated on the fluorophenyl ring.  Hydroxylated metabolites have been detected 
from similar bicyclic aromatic compounds incubated with this fungus, but none that 
contain the pyridyl moiety.  Indeed, pyridine-containing substrates are often 
biotransformed to N-oxides by C. elegans (Parshikov et al., 2012), and (Zeng et al., 
2012) reported that 3-(N-Boc-aminomethyl)-5-bromopyridine was oxidized to the N-
oxide by C. echinulata.  With the substrates 1-5 employed in this study (Figure 2) no N-
oxidation was observed. 
The site of fluorine substitution had an influence on the extent of oxidation; thus 
compound 2, in which the fluorine is at C-3’, was almost entirely biotransformed after 
24 h incubation with C. elegans, whereas compound 3 (fluorine at C-2’) was 
biotransformed to a much lesser degree and compound 4 (fluorine at C-4’) was not 
biotransformed at all.  Based on our previous studies with the related substrates 
fluorobiphenyl (Amadio and Murphy, 2010, Bright et al., 2013) and flurbiprofen 
(Amadio et al., 2010, Shaughnessy et al., 2014), the 4’ position is predominantly 
hydroxylated and if replaced with fluorine, no hydroxylation is observed, which would 
account for the absence of hydroxylation of 4.  Furthermore, 2, 3 and 5 were similarly 
regiospecifically hydroxylated at C4’ by the fungus.   
Some researchers have correlated the regiospecificity of cytochrome P450-
catalysed hydroxylation of aromatic compounds with calculated frontier orbital density 
distribution (Koerts et al., 1997, Rietjens et al., 1993). Here, calculated frontier orbital 
density distributions at high-level computations (see supporting information for details) 
confirm the regiospecificity of CYP-catalysed hydroxylation for compounds 1-3 and 5 
where the highest HOMO densities are found at the 4’ carbon sites in these starting 
molecules.  Interestingly, the calculated atomic charges (Table S1) for C4’ of all the 
substrates reveal that compound 2 has the highest negative charge, which might account 
for this compound being most readily hydroxylated (Table 1). 
The site of phenyl ring substitution on pyridyl seems to determine whether the 
carboxyl is reduced, as in compounds 1 and 5, where the phenyl is para to the carboxyl 
group and yielded the corresponding alcohol after 24 h incubation.  Only the carboxylic 
acid is observed after 48 h, thus the alcohol is re-oxidised.  None of the other 
compounds (2-4), which had fluorophenyl substituents meta to the carboxyl group, were 
reduced in this way.  Interestingly, fluorinated biphenyl-4-carboxylic acids underwent 
similar reduction and re-oxidation of the carboxylate when incubated with C. elegans 
(Bright et al., 2013), but the hydroxylated alcohols were also detected as intermediates, 
whereas with the 1 and 5, only the hydroxylated carboxylic acids were identified.  It is 
likely that a carboxylate reductase, which has been identified in other fungi (Winkler 
and Winkler, 2016, Ma et al., 2011) and requires ATP and NADPH as co-substrates, is 
responsible for the reduction.  It is conceivable that as incubation time progresses and in 
the absence of any added nutrient, the redox balance in the cell results in the reverse 
reaction dominating, thus the carboxylic acid is produced. 
Rat liver microsomes were unable to transform any of the fluorophenyl pyridine 
carboxylic acids, most likely because these compounds are inhibitors of the CYPs 
present.  Pyridine inhibits rabbit liver microsomes (Kaul and Novak, 1987) and 
interestingly the N-oxide metabolite is formed, but no such metabolite was observed 
with 2.  It is possible that the whole cells of C. elegans are more resilient to the 
inhibitory effects of the substrates in comparison to microsomes, which underscores the 
effectiveness of the fungal system as a mammalian proxy for in vitro assessment of 
xenobiotic biotransformation. 
Studies of the human metabolism of voraxapar and tedizolid phosphate have 
revealed that the drugs are not degraded to a point where fluorophenyl pyridine is 
formed as a discrete metabolite (Ghosal et al., 2011; Ong et al., 2014).  Nevertheless, it 
is likely that this structural motif will be incorporated into future pharmaceutical agents, 
thus understanding the likely phase I metabolism arising from related model 
compounds, such as 2-5, will help in the prediction of the likely metabolites formed. 
Conclusions 
This study demonstrates that Cunninghamella elegans is able to produce hydroxylated 
metabolites of fluorophenyl pyridine carboxylic acids, and that the extent and 
regioselectivity of hydroxylation is dependent on the position of the fluorine substituent.  
The absence of biotransformation products in microsomal incubations illustrates the 
usefulness of the fungus in generating difficult-to-obtain metabolites of relevant 
xenobiotics and drug-like molecules to enable a comprehensive understanding of their 
metabolism. 
 
 
Supporting Information 
Computational details on compounds 1-11 including calculated frontier orbital densities and 
atomic charges of carbon atoms for 1-5 and 19F GIAO-NMR shifts for 2-5 and 8-11. 
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Table 1. 19F NMR analysis of the biotransformation products 8-11 from compounds 2-5 
in C. elegans. The observed 19F NMR shifts are in excellent agreement with predicted 
GIAO-NMR shifts (see supporting information). 
 
Compound Substrate δF (ppm) Fluorometabolite(s) δF (ppm) Compound Yield 
2 -112.5 -135.6  8 95% 
3 -118.6 -116.9 9 22% 
4 -113.2     N.D.   
5 -116.7 -114.0, -117.5 10, 11 36%, 59% 
N.D. Not detected 
 
Table 2.  GC-MS analysis of silylated substrates and metabolites from the 
biotransformation of compounds 1-5 by C. elegans. Each –OH group in compounds (1-
11) is replaced by a –OSiMe3 group after silylation. 
 
Compound   tR (min)  m/z M
+  Metabolite tR (min)  Metabolite m/z M
+ 
1  10.75  271  9.18, 14.16  257, 359 
2   9.89  289  13.33  377  
3   9.93  289  13.26  377 
4  10.04  289  N.D.  N.D. 
5   10.15  289  9.45, 13.62   275, 377 
 
Figure 1 
 
Figure 2 
1
2
3
4
5
6
1'
2'
3'
4'
5'
6'
 2
 3  4
 1
 5
 
Figure 3 
 8
 9
 10
 C.elegans
 C.elegans
 C.elegans
 2
 3
 5
 7
 C.elegans
 1  6
 11
Figure 4 
 
4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00
200000
600000
1000000
1400000
1800000
2200000
2600000
3000000
3400000
Time (min)
A
b
u
n
d
a
n
c
e
4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
1200000
Time (min)
A
b
u
n
d
a
n
c
e
Time= 0
Time= 24 h
Time= 48 h
4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
2400000
2600000
Time (min)
A
b
u
n
d
a
n
c
e
1
7
6
 
 Figure 5 
4’-OH-Flurbiprofen
16.00 16.10 16.20 16.30 16.40 16.50 16.60 16.70 16.80 16.90
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
150000
160000
170000
Time (min)
A
b
u
n
d
a
n
c
e
16.00 16.10 16.20 16.30 16.40 16.50 16.60 16.70 16.80 16.90
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
150000
160000
170000
Time (min)
A
b
u
n
d
a
n
c
e
16.00 16.10 16.20 16.30 16.40 16.50 16.60 16.70 16.80 16.90
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
150000
160000
170000
Time (min)
A
b
u
n
d
a
n
c
e
0 mM 2
0.25 mM 2
0.125 mM 2
 
Figure captions 
Figure 1.  Structures of the recently FDA-approved fluorinated drugs Sivextro and 
Zontivity. 
Figure 2.  Structures of the pyridine carboxylic acids 1-5 used in this study.  
Figure 3.  Hydroxylated biotransformation products 6-11 formed upon incubation of 
pyridine carboxylic acids 1, 2, 3 and 5.  The site of hydroxylation of 6 was predicted 
based on the other biotransformation products and GC-MS data. 
Figure 4.  Total ion chromatograms of the biotransformation products 6 and 7 from 1 
after different incubation periods. 
Figure 5.  Total ion chromatograms of the 4’-hydroxylated microsomal 
biotransformation product of flurbiprofen formed in the presence of various 
concentrations of 2. 
